IL17RB and neoplasm: Therefore, future therapeutic strategies should emphasise mechanism‐selective modulation – for instance, small molecules or targeted protein degraders that disrupt oncogenic interfaces within the Wnt/CRL4 adaptor complex – while integrating tumour‐selective delivery approaches such as hepatotropic GalNAc–siRNA, liver‐tropic lipid nanoparticles or loco‐regional administration for LIHC.